VIAN Therapeutics
1 known investors
VIAN Therapeutics develops a topical eye drop treatment for retinal diseases caused by angiogenesis and vascular permeability, offering a non-invasive alternative to intravitreal injections. The lead candidate targets age-related macular degeneration and diabetic macular edema by inhibiting pro-angiogenic factors and inflammatory cytokines.
BiotechHealthtechMedical Devices
Founders & leadership
JP
Juan Pablo Robles AlvarezCEO and Founder
Investors · 1
Competitors · 6
by search overlap
Vividion Therapeutics4 shared keywordsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Elevian4 shared keywordsElevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
Vivian Health4 shared keywordsVivian is an online marketplace connecting healthcare professionals with staff, travel, local contract, and per diem jobs from employers and recruiters. It lets job seekers compare listings and communicate with recruiters in one place.
Vivan Therapeutics3 shared keywordsVivantX works in precision oncology, applying tumour molecular profiling and personalized therapeutics to cancer care. The company draws on advisors in medical and clinical oncology, data science, and digital health.
Vivace Therapeutics3 shared keywordsVivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types. The company adopts a capital-efficient approach to advance novel cancer therapeutics, with potential applications also in fibrotic disease.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies competing with VIAN Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does VIAN Therapeutics do?
- VIAN Therapeutics develops a topical eye drop treatment for retinal diseases caused by angiogenesis and vascular permeability, offering a non-invasive alternative to intravitreal injections. The lead candidate targets age-related macular degeneration and diabetic macular edema by inhibiting pro-angiogenic factors and inflammatory cytokines.
- Who founded VIAN Therapeutics?
- VIAN Therapeutics was founded by Juan Pablo Robles Alvarez.
- Who are VIAN Therapeutics's investors?
- VIAN Therapeutics's investors include Ulu Ventures.